Manufacturing, regulatory complexities slow biosimilars

03/18/2013 | Genetic Engineering & Biotechnology News

Merck, Teva, Lonza and Samsung are among the companies that have scaled back plans to produce biosimilar versions of brand-name biologic drugs amid regulatory uncertainty, market volatility and high development and manufacturing costs. Bringing a biosimilar to market can cost up to $250 million by some estimates and can take six to nine years, compared with $1 million to $2 million and three years for a generic small-molecule drug.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX